4.5 Review

Nanomaterial-Based Antifungal Therapies to Combat Fungal Diseases Aspergillosis, Coccidioidomycosis, Mucormycosis, and Candidiasis

期刊

PATHOGENS
卷 10, 期 10, 页码 -

出版社

MDPI
DOI: 10.3390/pathogens10101303

关键词

nanomaterials; antifungal therapies; aspergillosis; coccidioidomycosis; mucormycosis; candidiasis

资金

  1. Universidad Autonoma de Nuevo Leon
  2. CONACyT [221332]
  3. Fronteras de la Ciencia grant 1502 Infraestructura Grant [279957]
  4. Apoyo a la Ciencia de Frontera Grant [316869]
  5. Beca Nacional de Posgrado from CONACyT
  6. Beca de Posdoctorado Nacional
  7. CONACyT through Paicyt 2019-2020 Science Grant
  8. CONACyT through Paicyt 2020-2021 Science Grant
  9. CONACyT through Paicyt 2021-2022 Science Grant

向作者/读者索取更多资源

Invasive infections caused by filamentous fungi, such as Aspergillus and Mucorales, pose a serious threat to public health, particularly for immunosuppressed individuals and patients with conditions like HIV/AIDS. Nanoformulations have been developed to improve efficacy and lessen adverse effects of conventional antifungal treatments, but therapeutic options for coccidioidomycosis and mucormycosis remain limited. Further research is needed to develop new therapeutic alternatives in this field.
Over the last years, invasive infections caused by filamentous fungi have constituted a serious threat to public health worldwide. Aspergillus, Coccidioides, Mucorales (the most common filamentous fungi), and Candida auris (non-filamentous fungus) can cause infections in humans. They are able to cause critical life-threatening illnesses in immunosuppressed individuals, patients with HIV/AIDS, uncontrolled diabetes, hematological diseases, transplantation, and chemotherapy. In this review, we describe the available nanoformulations (both metallic and polymers-based nanoparticles) developed to increase efficacy and reduce the number of adverse effects after the administration of conventional antifungals. To treat aspergillosis and infections caused by Candida, multiple strategies have been used to develop new therapeutic alternatives, such as incorporating coating materials, complexes synthesized by green chemistry, or coupled with polymers. However, the therapeutic options for coccidioidomycosis and mucormycosis are limited; most of them are in the early stages of development. Therefore, more research needs to be performed to develop new therapeutic alternatives that contribute to the progress of this field.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据